A Phase 4 interventional study of ursodeoxycholic acid in Short Bowel Syndrome, sponsored by Jinling Hospital, China. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-02-24.
Sponsored by Jinling Hospital, China · Phase 4, Interventional, and Prevention
The efficacy of UDCA in treating the parenteral nutrition-associated cholestasis(PNAC) has been identified by some studies in children without short bowel syndrome(SBS).Most of the adults who suffering PNAC have SBS. it limits the potential function of UDCA because of the lack of SBS patients and malabsorption of UDCA.Therefore, we design this clinical trial in our center of SBS to approach the preventative and therapeutical effect of UDCA to PNAC in adults with short bowel syndrome.
149 studies on the registry are indexed under Short Bowel Syndrome; 25 are open to participants now.
This study's enrollment of 30 is above the median of 20 across 100 interventional studies indexed under Short Bowel Syndrome.
Browse Short Bowel Syndrome studies →Jinling Hospital, China is the lead sponsor of 126 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
15-30mg/kg/d UDCA for 2 months + placebo for 2 months
Drug: ursodeoxycholic acid
placebo for 2 months+15-30mg/kg/d UDCA for 2 months
Drug: ursodeoxycholic acid
The biochemical indicator of patients' liver function during oral UDCA or placebo
detect the biochemical indicator of patients' liver function(Serum bilirubin, GGT Valley, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase) during oral UDCA or placebo
Time frame: 2 months
the changs of composition of serum bile acid after oral UDCA or placebo
we test the composition of serum bile acid at the beginning,2 months,4 months(the end) of the trial
Time frame: 2 months
The changs of the level of fibroblast growth factor 19(FGF19) in the serum
we test the level of FGF19 in the serum at the beginning,2 months,4months(the end) of the trail.
Time frame: 4 months
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jinling Hospital, China